Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 151 to 175 of 1147 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
99 decreased regulation of gene expression (GO:0010468) androgen receptor (PR:000004191) 286: Altered, Transcription of genes by the androgen receptor
101 increased aryl hydrocarbon receptor activity (GO:0004874) aryl hydrocarbon receptor (PR:000003858) 18: Activation, AhR
185 decreased gene expression (GO:0010467) 3-hydroxyacyl-CoA dehydrogenase type-2 (PR:000008774) 140: Decreased, HSD17B10 expression
105 morphological change abnormal cardiovascular system physiology (MP:0001544) 317: Altered, Cardiovascular development/function
106 increased gene expression (GO:0010467) prostaglandin G/H synthase 2 (PR:000013428) 1269: Increase, COX-2 expression
107 increased androgen receptor activity (GO:0004882) androgen receptor (PR:000004191) 25: Agonism, Androgen receptor
108 decreased gene expression (GO:0010467) vitellogenins (MESH:D014819) 285: Reduction, Vitellogenin synthesis in liver
110 decreased vitellogenins (MESH:D014819) 221: Reduction, Plasma vitellogenin concentrations
111 decreased receptor-mediated endocytosis (GO:0006898) vitellogenins (MESH:D014819) 309: Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
112 decreased oocyte growth (GO:0001555) 309: Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
113 decreased oocyte development (GO:0048599) 309: Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
115 decreased Follicle stimulating hormone (CHEBI:81569) 129: Reduction, Gonadotropins, circulating concentrations
116 decreased calcium-transporting ATPase activity (GO:0005388) calcium ion-transporting ATPase complex (GO:0090534) 51: Inhibition, Ca++ ATPase
117 increased calcium ion (CHEBI:39124) 50: Increase, Ca++ (intracellular)
118 disrupted mitochondrial respiratory chain (GO:0005746) 178: Mitochondrial electron transport chain, disrupted
120 increased reactive oxygen species biosynthetic process (GO:1903409) reactive oxygen species (CHEBI:26523) 1115: Increase, Reactive oxygen species
121 decreased nitric oxide (CHEBI:16480) 193: Decreased, Nitric Oxide
122 decreased long-term synaptic potentiation (GO:0060291) 166: Decreased, Long-term potentiation (LTP)
124 decreased transport (GO:0006810) bile salt export pump (PR:000003549) 41: Inhibition, Bile Salt Export Pump (ABCB11)
125 increased gene expression (GO:0010467) bile acid receptor (PR:000011396) 288: Activation of specific nuclear receptors, Transcriptional change
126 increased bile (UBERON:0001970) 214: Bile accumulation, Pathological condition
127 increased cytokine secretion (GO:0050663) Cytokine (FMA:84050) 87: Release, Cytokine
169 increased gene expression (GO:0010467) platelet glycoprotein 4 (PR:000001905) 54: Up Regulation, CD36
1147 increased protein oxidation (GO:0018158) 1767: Increase, Protein oxidation
173 increased fatty acid synthase activity (GO:0004312) fatty acid synthase (PR:000007348) 116: Activation, FAS